Stay updated on Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial page.

Latest updates to the Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedFooter/versioning notes were updated: added 'Revision: v3.3.3' and removed 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2'.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check44 days agoChange DetectedThe page no longer displays the site-wide government funding/operating status notice. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check58 days agoChange DetectedThe new screenshot shows the same ClinicalTrials.gov study record with no changes to core information such as title, sponsor, locations, eligibility criteria, or outcomes; only minor UI and formatting adjustments are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check87 days agoChange Detected- Updated the page to include a government-operating-status notice and a new version tag (v3.2.0), replacing the old v3.1.0.SummaryDifference4%

- Check94 days agoChange DetectedUpdate: version bumped to v3.1.0 and new contact details added (oncosohn@yuhs.ac) with a corresponding informational identifier; previous version v3.0.2 is removed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Paclitaxel in HR+ MBC Clinical Trial page.